Investigators found 10 main themes characterizing the differences between primary care clinics classified as high- and low-performing in distributing diabetes care.
The main difference between high- and low-performing diabetes care clinics is the adoption of approaches aimed at leveraging data-driven proactive patient outreach as a tool to intensify treatment, according to a recent study.
The investigators said that physicians should consider the results of the study, published in The Annals of Family Medicine, and the potential value that incorporating a paradigm like this can have on diabetes care.
“Perhaps there are other stages in the development of innovations for practice transformation; in the meantime, these findings should be considered by leaders interested in improving care for patients with diabetes and other chronic conditions,” wrote the investigators.
A previous study found that the measures of diabetes care outcomes did not improve from 2005 to 2016, despite a significant rise in national campaigns to improve diabetes control and an overall improvement in treatment options.
However, the percentage of Minnesota patients with diabetes who achieved optimal care increased from 12% to 45% between 2004 and 2017, differing from the rest of the nation, which plateaued at 23% from 2013 to 2016. The investigators attributed the variance to an emphasis on performance monitoring and public reporting.
In light of that study, researchers of the present analysis used quantitative data to determine what factors determine whether a Minnesota clinic are considered high- or low-performing. They distributed surveys to primary care clinics that participated in the previous study, of which 416 completed them. Respondents were asked to report whether care management processes were present and rate their clinic’s priority for improving diabetes care in the next year.
After returning the survey, clinic leaders were asked to participate in a 20-to-30-minute interview to discuss their approaches to diabetes care.
The clinics were identified as high-, middle-, or low-performing based on their scores from the Minnesota Community Measurement. From the survey results, the investigators identified 10 themes that offered insight into the factors and methods characterizing the performance groups:
The main difference between groups was that high-performing clinics were much more likely to report using proactive care compared with low-performing clinics, who either didn’t mention those strategies or cited barriers to implementing them. Middle-performing clinics mostly reported that they just starting to adopt proactive approaches or viewed them as a wish.
High-performing clinics relied on timely and accurate reports to identify individual patients that were falling behind treatment goals and address their need without waiting for them to ask or come in for a scheduled appointment.
The investigators also said that they were surprised with how few comments they received, across all performance groups, regarding effective care management processes, with the exception of distributing diabetes education.
The middle-performing group had the most comments regarding effective care management processes and had the highest scores on the survey of diabetes process, suggesting, “that a clinic can obtain good performance by implementing these processes, but to break through to high performance, a paradigm shift is needed to add proactive care,” wrote the researchers.
The investigators identified the small group of clinics used, only sampling from one state, including few low-performing clinics, and indirect measurements of socioeconomic status as study limitations. They said that their results should be considered preliminary and that future studies confirming the results need to be conducted.
Reference
Solberg LI, Peterson KA, Fu H, Eder M, Jacobson R, Carlin CS. Strategies and factors associated with top performance in primary care for diabetes: insights from a mixed methods study. Ann. Fam. Med. March 2021;19(2):110-116. doi:10.1370/afm.2646
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More